Lista de obras -

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

artículo científico publicado en 1993

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

artículo científico publicado en 2005

A durable response to cytarabine in advanced breast cancer ⬇️

artículo científico publicado el 1 de enero de 1997

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

artículo científico publicado en 2010

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

artículo científico publicado en 2010

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium ⬇️

artículo científico publicado el 12 de marzo de 2011

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel ⬇️

artículo científico publicado el 11 de octubre de 2010

Advances in prediction for ovarian cancer treatment stratification

scientific article published on 01 February 2019

Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study

artículo científico publicado en 2003

Better therapeutic trials in ovarian cancer

artículo científico publicado en 2014

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

artículo científico publicado en 2006

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

artículo científico publicado en 2007

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

artículo científico publicado en 2005

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009

artículo científico publicado en 2010

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

artículo científico publicado en 2011

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial

artículo científico publicado en 2012

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study

artículo científico publicado en 2009

Epothilones in the Treatment of Ovarian Cancer ⬇️

artículo científico publicado el 1 de abril de 2011

Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment

artículo científico publicado en 2010

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

artículo científico publicado en 2014

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

artículo científico publicado en 2013

Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital ⬇️

artículo científico publicado el 1 de mayo de 1992

Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients ⬇️

artículo científico publicado el 1 de julio de 1995

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

artículo científico publicado en 2023

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

artículo científico publicado en 2014

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

artículo científico publicado en 2016

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

artículo científico publicado en 2016

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study ⬇️

artículo científico publicado el 19 de agosto de 2011

Optimal chemotherapy treatment for women with recurrent ovarian cancer

artículo científico publicado en 2007

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention

artículo científico publicado en 2016

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas ⬇️

artículo científico publicado el 28 de enero de 2011

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks ⬇️

artículo científico publicado el 1 de marzo de 1998

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors

artículo científico publicado en 2000

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

artículo científico publicado en 2005

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

artículo científico publicado en 2004

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

artículo científico publicado en 2011

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

artículo científico publicado en 2010

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.

artículo científico publicado en 2011

Pituitary apoplexy following isosorbide administration

artículo científico publicado en 1987

Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada

artículo científico publicado en 2006

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer ⬇️

artículo científico publicado el 1 de agosto de 2010

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

artículo científico publicado en 2011

Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease ⬇️

artículo científico publicado el 1 de noviembre de 1991

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease ⬇️

artículo científico publicado el 1 de septiembre de 1995

Rethinking ovarian cancer: recommendations for improving outcomes

artículo científico publicado en 2011

Short term therapy (STT) for acute myelogenous leukaemia (AML)

artículo científico publicado el 1 de enero de 1992

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium ⬇️

artículo científico publicado el 1 de julio de 2010

Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial

artículo científico publicado en 2002

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179) ⬇️

artículo científico publicado el 29 de marzo de 2011

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

artículo científico publicado en 2014

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period ⬇️

artículo científico publicado el 1 de marzo de 1993

The statins as anticancer agents

artículo científico publicado en 2003

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).

artículo científico publicado en 2013

Lista de obras de

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

A durable response to cytarabine in advanced breast cancer ⬇️

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium ⬇️

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel ⬇️

Advances in prediction for ovarian cancer treatment stratification

Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study

Better therapeutic trials in ovarian cancer

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study

Epothilones in the Treatment of Ovarian Cancer ⬇️

Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital ⬇️

Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients ⬇️

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study ⬇️

Optimal chemotherapy treatment for women with recurrent ovarian cancer

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention

Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas ⬇️

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks ⬇️

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.

Pituitary apoplexy following isosorbide administration

Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer ⬇️

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease ⬇️

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease ⬇️

Rethinking ovarian cancer: recommendations for improving outcomes

Short term therapy (STT) for acute myelogenous leukaemia (AML)

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium ⬇️

Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179) ⬇️

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period ⬇️

The statins as anticancer agents

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).